NM_003850.3:c.1099G>A

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_003850.3(SUCLA2):​c.1099G>A​(p.Asp367Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00545 in 1,613,104 control chromosomes in the GnomAD database, including 404 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D367Y) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0094 ( 66 hom., cov: 32)
Exomes 𝑓: 0.0050 ( 338 hom. )

Consequence

SUCLA2
NM_003850.3 missense

Scores

3
7
7

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: 7.51

Publications

5 publications found
Variant links:
Genes affected
SUCLA2 (HGNC:11448): (succinate-CoA ligase ADP-forming subunit beta) Succinyl-CoA synthetase (SCS) is a mitochondrial matrix enzyme that acts as a heterodimer, being composed of an invariant alpha subunit and a substrate-specific beta subunit. The protein encoded by this gene is an ATP-specific SCS beta subunit that dimerizes with the SCS alpha subunit to form SCS-A, an essential component of the tricarboxylic acid cycle. SCS-A hydrolyzes ATP to convert succinate to succinyl-CoA. Defects in this gene are a cause of myopathic mitochondrial DNA depletion syndrome. A pseudogene of this gene has been found on chromosome 6. [provided by RefSeq, Jul 2008]
SUCLA2 Gene-Disease associations (from GenCC):
  • Leigh syndrome
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
    Inheritance: Mitochondrial, AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.004880607).
BP6
Variant 13-47954148-C-T is Benign according to our data. Variant chr13-47954148-C-T is described in ClinVar as Benign. ClinVar VariationId is 139362.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.0668 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_003850.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SUCLA2
NM_003850.3
MANE Select
c.1099G>Ap.Asp367Asn
missense
Exon 8 of 11NP_003841.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SUCLA2
ENST00000646932.1
MANE Select
c.1099G>Ap.Asp367Asn
missense
Exon 8 of 11ENSP00000494360.1
SUCLA2
ENST00000643023.1
c.1162G>Ap.Asp388Asn
missense
Exon 9 of 12ENSP00000495664.1
SUCLA2
ENST00000642944.1
c.925G>Ap.Asp309Asn
missense
Exon 8 of 11ENSP00000495674.1

Frequencies

GnomAD3 genomes
AF:
0.00936
AC:
1422
AN:
151948
Hom.:
62
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00237
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0695
Gnomad ASJ
AF:
0.000577
Gnomad EAS
AF:
0.0427
Gnomad SAS
AF:
0.00208
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000235
Gnomad OTH
AF:
0.00669
GnomAD2 exomes
AF:
0.0170
AC:
4253
AN:
250876
AF XY:
0.0131
show subpopulations
Gnomad AFR exome
AF:
0.00197
Gnomad AMR exome
AF:
0.0944
Gnomad ASJ exome
AF:
0.00119
Gnomad EAS exome
AF:
0.0460
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000141
Gnomad OTH exome
AF:
0.0113
GnomAD4 exome
AF:
0.00503
AC:
7353
AN:
1461038
Hom.:
338
Cov.:
31
AF XY:
0.00455
AC XY:
3305
AN XY:
726818
show subpopulations
African (AFR)
AF:
0.00150
AC:
50
AN:
33436
American (AMR)
AF:
0.0957
AC:
4271
AN:
44632
Ashkenazi Jewish (ASJ)
AF:
0.00161
AC:
42
AN:
26116
East Asian (EAS)
AF:
0.0626
AC:
2483
AN:
39674
South Asian (SAS)
AF:
0.000986
AC:
85
AN:
86218
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53378
Middle Eastern (MID)
AF:
0.000521
AC:
3
AN:
5762
European-Non Finnish (NFE)
AF:
0.0000810
AC:
90
AN:
1111482
Other (OTH)
AF:
0.00545
AC:
329
AN:
60340
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
317
634
952
1269
1586
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
100
200
300
400
500
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00942
AC:
1432
AN:
152066
Hom.:
66
Cov.:
32
AF XY:
0.0106
AC XY:
791
AN XY:
74332
show subpopulations
African (AFR)
AF:
0.00236
AC:
98
AN:
41496
American (AMR)
AF:
0.0703
AC:
1073
AN:
15272
Ashkenazi Jewish (ASJ)
AF:
0.000577
AC:
2
AN:
3464
East Asian (EAS)
AF:
0.0424
AC:
220
AN:
5184
South Asian (SAS)
AF:
0.00187
AC:
9
AN:
4802
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10542
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000235
AC:
16
AN:
67986
Other (OTH)
AF:
0.00662
AC:
14
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
66
131
197
262
328
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00310
Hom.:
12
Bravo
AF:
0.0157
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.00159
AC:
7
ESP6500EA
AF:
0.000465
AC:
4
ExAC
AF:
0.0132
AC:
1607
Asia WGS
AF:
0.0210
AC:
72
AN:
3478
EpiCase
AF:
0.0000546
EpiControl
AF:
0.000237

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:4
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 30, 2011
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Jun 29, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jan 28, 2016
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria Benign:3
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease.

Nov 11, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:2
Jun 13, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.57
BayesDel_addAF
Benign
-0.33
T
BayesDel_noAF
Benign
-0.18
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Benign
0.31
T
Eigen
Uncertain
0.60
Eigen_PC
Uncertain
0.66
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.97
D
MetaRNN
Benign
0.0049
T
MetaSVM
Benign
-0.52
T
MutationAssessor
Uncertain
2.4
M
PhyloP100
7.5
PrimateAI
Uncertain
0.75
T
PROVEAN
Uncertain
-4.4
D
REVEL
Pathogenic
0.73
Sift
Benign
0.10
T
Sift4G
Benign
0.086
T
Polyphen
0.88
P
Vest4
0.28
MPC
0.62
ClinPred
0.033
T
GERP RS
5.5
Varity_R
0.49
gMVP
0.91
Mutation Taster
=16/84
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs117412559; hg19: chr13-48528283; COSMIC: COSV66222679; COSMIC: COSV66222679; API